Media coverage about Simulations Plus (NASDAQ:SLP) has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Simulations Plus earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media headlines about the technology company an impact score of 44.5510812184361 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of SLP stock traded up $0.05 during mid-day trading on Wednesday, hitting $15.90. 32,296 shares of the stock traded hands, compared to its average volume of 52,329. Simulations Plus has a 52 week low of $10.40 and a 52 week high of $17.45. The company has a market capitalization of $279.28, a P/E ratio of 44.86 and a beta of -0.63.
Simulations Plus (NASDAQ:SLP) last released its earnings results on Tuesday, January 9th. The technology company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. The business had revenue of $7.07 million during the quarter, compared to the consensus estimate of $6.57 million. Simulations Plus had a net margin of 23.78% and a return on equity of 24.56%. equities research analysts predict that Simulations Plus will post 0.4 EPS for the current year.
In related news, CEO Walter S. Woltosz sold 18,500 shares of the firm’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $16.25, for a total value of $300,625.00. Following the completion of the transaction, the chief executive officer now owns 5,502,416 shares of the company’s stock, valued at $89,414,260. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 55,500 shares of company stock valued at $899,655. 33.45% of the stock is owned by insiders.
About Simulations Plus
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.